COVID-19 Repeated Convalescent Plasma Collection: Analysis of 149 Donations from 88 French Military Health Workers.
COVID-19
Convalescent plasma
Passive immunization
Journal
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie
ISSN: 1660-3796
Titre abrégé: Transfus Med Hemother
Pays: Switzerland
ID NLM: 101176417
Informations de publication
Date de publication:
20 Aug 2021
20 Aug 2021
Historique:
received:
07
11
2020
accepted:
16
02
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Passive therapy with convalescent plasma (CP) could be an effective and safe treatment option in COVID-19 patients. Neutralizing antibodies present in CP generated in response to SARS-CoV-2 infection and directed against the receptor-binding domain of the spike protein are considered to play a major role in the viral clearance. CP infusion may also contribute to the modulation of the immune response through its immunomodulatory effect. We describe for the first time the effectiveness of a CP collection protocol from repeated donations in young patients. We enrolled health service workers who experienced mild to moderate COVID-19 and from whom several donations have been collected. No minimal severity threshold and no biological cure criteria were required. Donors could return to a second plasma donation 14 days after the first donation. A minimal neutralizing antibody titer of 1:40 was considered for clinical use. Eighty-eight donors were included (median age 35 [28-48] years, 41 women), and 149 plasma products were collected. COVID-19 were mainly WHO stage 2 infections (96%). Among the 88 first donations, 76% had neutralizing antibody titers higher than or equal to 1:40. Eighty-eight percent of donors who came for a second donation had a neutralizing antibody titer of 1:40. Median durations were 15 (15-19) and 38 (33-46) days from the first to the second donation and from recovery to the second donation, respectively. Sixty-nine percent of donors who came for a third donation had a neutralizing antibody titer of 1:40. Median durations were 16 (13-37) and 54 (49-61) days from the second to the third donation and from recovery to the third donation, respectively. No significant difference was observed between the IgG ratio and the age of the donors or the time between recovery and donation. The average IgG ratio did not significantly vary between donations. When focused on repeated blood donors, no significant differences were observed either. The recruitment of young patients with a mild to moderate CO-VID-19 course is an efficient possibility to collect CP with a satisfactory level of neutralizing antibodies. Repeated donations are a well-tolerated and effective way of CP collection.
Sections du résumé
BACKGROUND
BACKGROUND
Passive therapy with convalescent plasma (CP) could be an effective and safe treatment option in COVID-19 patients. Neutralizing antibodies present in CP generated in response to SARS-CoV-2 infection and directed against the receptor-binding domain of the spike protein are considered to play a major role in the viral clearance. CP infusion may also contribute to the modulation of the immune response through its immunomodulatory effect. We describe for the first time the effectiveness of a CP collection protocol from repeated donations in young patients.
MATERIALS AND METHODS
METHODS
We enrolled health service workers who experienced mild to moderate COVID-19 and from whom several donations have been collected. No minimal severity threshold and no biological cure criteria were required. Donors could return to a second plasma donation 14 days after the first donation. A minimal neutralizing antibody titer of 1:40 was considered for clinical use.
RESULTS
RESULTS
Eighty-eight donors were included (median age 35 [28-48] years, 41 women), and 149 plasma products were collected. COVID-19 were mainly WHO stage 2 infections (96%). Among the 88 first donations, 76% had neutralizing antibody titers higher than or equal to 1:40. Eighty-eight percent of donors who came for a second donation had a neutralizing antibody titer of 1:40. Median durations were 15 (15-19) and 38 (33-46) days from the first to the second donation and from recovery to the second donation, respectively. Sixty-nine percent of donors who came for a third donation had a neutralizing antibody titer of 1:40. Median durations were 16 (13-37) and 54 (49-61) days from the second to the third donation and from recovery to the third donation, respectively. No significant difference was observed between the IgG ratio and the age of the donors or the time between recovery and donation. The average IgG ratio did not significantly vary between donations. When focused on repeated blood donors, no significant differences were observed either.
CONCLUSION
CONCLUSIONS
The recruitment of young patients with a mild to moderate CO-VID-19 course is an efficient possibility to collect CP with a satisfactory level of neutralizing antibodies. Repeated donations are a well-tolerated and effective way of CP collection.
Identifiants
pubmed: 34580580
doi: 10.1159/000515843
pii: tmh-0395-0001
pmc: PMC8450834
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-6Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
SN Compr Clin Med. 2020;2(8):1120-1131
pubmed: 32838169
Int J Infect Dis. 2015 Dec;41:3-5
pubmed: 26482389
Clin Microbiol Rev. 2000 Oct;13(4):602-14
pubmed: 11023960
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Antiviral Res. 2020 Sep;181:104880
pubmed: 32679056
Emerg Infect Dis. 2016 Sep;22(9):1554-61
pubmed: 27532807
J Clin Invest. 2020 Oct 1;130(10):5112-5114
pubmed: 32634126
Transfusion. 2020 Jul;60(7):1643-1644
pubmed: 32428966
Transfusion. 2020 Oct;60(10):2189-2191
pubmed: 32533556
Front Immunol. 2020 Aug 07;11:1949
pubmed: 32849654
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Front Microbiol. 2020 Oct 19;11:584251
pubmed: 33193227
Cureus. 2020 Aug 3;12(8):e9535
pubmed: 32905148
Curr Opin HIV AIDS. 2015 May;10(3):129-34
pubmed: 25760933
Open Biol. 2020 Sep;10(9):200174
pubmed: 32898468
J Clin Invest. 2020 Oct 1;130(10):5235-5244
pubmed: 32634129
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Med Virol. 2005 Oct;77(2):147-50
pubmed: 16121363
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Transfus Apher Sci. 2017 Feb;56(1):31-34
pubmed: 28094110
Vox Sang. 2020 Aug;115(6):488-494
pubmed: 32240545
Euro Surveill. 2020 Jul;25(28):
pubmed: 32700670
Transfusion. 2020 Aug;60(8):1773-1777
pubmed: 32491199
Viral Immunol. 2008 Jun;21(2):123-32
pubmed: 18476771
Clin Infect Dis. 2020 Dec 17;71(10):2688-2694
pubmed: 32497196
Transfusion. 2020 Aug;60(8):1765-1772
pubmed: 32627216